Physician profile
John Will Bacon
NPI 1528724812
$2,489.93
in general payments reported to CMS, 2019-2025
24 companies · $723 in 2025
The $723 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $462 · 2023: $485 · 2024: $695 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,902.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $476.46 | 2022-2025 | Farxiga, Airsupra |
| Abbvie INC. | $418.02 | 2022-2025 | |
| Novo Nordisk INC | $339.70 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $279.70 | 2023-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $273.44 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Impel Pharmaceuticals INC. | $87.83 | 2022-2023 | Trudhesa |
| Novartis Pharmaceuticals Corporation | $79.89 | 2022-2023 | |
| Pfizer INC. | $74.16 | 2022-2025 | |
| Lundbeck LLC | $66.67 | 2025 | Rexulti |
| Exact Sciences Corporation | $63.49 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $43.52 | 2024-2025 | Dexcom G6 Transmitter |
| Actelion Pharmaceuticals US, INC. | $39.95 | 2025 | Opsumit |
| Phathom Pharmaceuticals, INC. | $35.29 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.20 | 2024 | |
| Kyowa Kirin, INC. | $24.80 | 2023 | Crysvita |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $23.03 | 2024 | Yupelri |
| Seqirus USA INC | $22.25 | 2025 | Flucelvax, Fluad |
| Otsuka America Pharmaceutical, INC. | $19.36 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.26 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $17.20 | 2023 | |
| Glaxosmithkline, LLC. | $16.20 | 2025 | Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $15.58 | 2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $14.49 | 2022 | |
| Medtronic, INC. | $14.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bacon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.